...Sirenade, which was founded in 2003 through the merger of kinase companies Nadag AG and SiReen AG...

...Sirenade , which was founded in 2003 through the merger of kinase companies Nadag and SiReen...

...AG and SiReen AG - combining Nadag's chemical kinase platform for hit and lead generation with SiReen's...

...Neurology, pain Clinical status: Phase II Founded: 2003 through the merger of Nadag AG and SiReen AG...

...service payments and is eligible for milestones. In January, German drug discovery companies Nadag and SiReen...

...service payments and is eligible for milestones. In January, German drug discovery companies Nadag and SiReen...

...Drug discovery companies Nadag and SiReen will merge in a stock transaction to form Sirenade Pharmaceuticals...
...AG , which will focus on CNS and oncology indications. The new company will combine SiReen's...
...platform for hit and lead generation. Nadag has one preclinical Alzheimer's disease (AD) program, and SiReen...

...Drug discovery companies Nadag (Munich, Germany) and SiReen (Munich, Germany) will merge to form Sirenade Pharmaceuticals...
...Sirenade Pharmaceuticals, which will focus on CNS and oncology indications. The new company will combine SiReen's...
...platform for hit and lead generation. Nadag has one preclinical Alzheimer's disease (AD) program, and SiReen...

...to treat peripheral vascular disease and as an adjunct to bypass surgery. - Aimee Dingwell SiReen's...
...chemistry specific only to a protein target when little is known about other similar proteins. SiReen AG...
...information to select active compounds that SiReen will synthesize to create focused libraries (see B3). SiReen...

...genomics technology to perform library synthesis and compound refinement. SiReen will pay EVT service fees. SiReen...
...2002 target identification deal (see BioCentury, April 1, 2002). Evotec OAI AG (FSE:EVT), Hamburg, Germany SiReen AG...